Subscribe to:
POZ magazine E-newsletters
POZ Personals Sign In / Join
Username:
Password:
Women's Hub News
 

Back to home » News & Views » Treatment News


 

January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007

emailrssprint

October 3, 2008

Tenofovir Linked to Mild Decrease in Kidney Function, but Not Kidney Disease

People taking a regimen that contains tenofovir (found in Viread, Truvada and Atripla) were more likely to experience mild decreases in kidney function over 144 weeks of treatment than people taking other antiretrovirals (ARVs), but they were no more likely to have serious kidney problems, according to a study published in the October 18 issue of AIDS.

Although clinical trials have not found higher rates of kidney disease among patients using tenofovir, several large cohort studies have found higher rates of mild reductions in a measure of kidney function called the glomerular filtration rate (GFR)—a sign of possible kidney problems—in tenofovir-treated patients compared with those using other nucleoside/nucleotide reverse transcriptase inhibitors.

To better determine tenofovir’s impact on kidney function, Joel Gallant, MD, from the Johns Hopkins University School of Medicine in Baltimore, and his colleagues combined and reanalyzed data from two Gilead Sciences-sponsored clinical trials, called 903 and 934. The analysis included 1,111 patients; 556 received an ARV regimen containing tenofovir, and 555 patients received a regimen containing either Zerit (stavudine) or Retrovir (zidovudine).

Dr. Gallant’s team found that the patients taking tenofovir were more likely to have small decreases in GFR, while those taking either Zerit or Retrovir were more likely to experience small increases. Generally, the decreases in GFR in patients taking tenofovir occurred within the first 96 weeks of treatment and did not progress to serious kidney disease. The difference in GFR between those on tenofovir versus other treatments was statistically significant, meaning that the difference was too large to have occurred by chance. The decrease in GFR in those on tenofovir, however, was so small that it is unlikely to cause symptoms or progress to kidney disease, and people on tenofovir were no more likely to experience serious kidney toxicity or to stop treatment due to kidney troubles than people taking Zerit or Retrovir.

NEW! Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team review all comments before they are posted. Please do not include either ":" or "@" in your comment.)

| Posting Rules

Previous Comments:

         


[Go to top]


Get Answers
What to do if you've just been diagnosed
How to find a support system
Things you should know before starting treatment
How to handle side effects and other concerns
How to tell someone you have HIV/AIDS

Blogs by HIV+ Women
Regan Ann Michelle Annette

Read the blogs
Woman of the Month
Brenda Lee Curry: Aging Gracefully With HIV
Founder, Copasetic Women, New York City

Overheard in the Women's Forum
"I am psychologically suffering from body wasting, mainly hips, face, legs and arms. Does anyone know where I can order something (maybe underwear with foam) to fill the sunken hips, so that pants can start looking normal? I feel pathetic when I look at myself in the mirror in jeans—jeans used to fill up so nicely, now they just hang!"

from Positive Women


Join the forums

Smart + Strong Network
POZ Magazine
POZ Personals
POZ Mentor
POZ ASO Directory
AIDSmeds
Real Health Magazine
TuSalud Magazine
ComboCards
Rx Info Cards
Also visit POZ on...
Facebook

MySpace

YouTube

 
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertise/contact us | site map]
© 2009 Smart + Strong. All Rights Reserved. Terms of use and Your privacy